78 patents
Utility
Method for treatment of rosacea in patients aged 65 years and older
9 Jan 24
A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
Filed: 21 Jan 21
Utility
Pharmaceutical compositions comprising silica microspheres
9 Jan 24
Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof.
Marina Shevachman, Amira Ze' Evi, Eilon Asculai, Batella Benyaminovich, Nir Avram, Chaim Aschkenasy
Filed: 17 Sep 20
Utility
Ruxolitinib or Deuterated Ruxolitinib Composition and Uses Thereof
21 Dec 23
This invention, in some embodiments thereof, relates to regimens, topical compositions comprising ruxolitinib, deuterated ruxolitinib or pharmaceutically acceptable salt thereof and uses thereof for the treatment of inflammatory skin conditions.
Moshe ARKIN, Ofer TOLEDANO, Karine NEIMANN
Filed: 17 Nov 21
Utility
Treatment of Skin Disorders with Compositions Comprising an Egfr Inhibitor
7 Dec 23
Provided herein compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib.
Moshe ARKIN, Marcel ZIGHELBOIM, Ori NOV, Ofer TOLEDANO, Karine NEIMANN
Filed: 22 Aug 23
Utility
Method for Treatment of Rosacea Including Patient Reported Outcomes Thereof
16 Nov 23
A regimen is described for the therapeutic treatment of rosacea including topically applying to the skin of a subject in need of the treatment a pharmaceutical composition.
Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
Filed: 24 Jul 23
Utility
Tapinarof Polymorphs
9 Nov 23
The present invention relates to crystalline polymorphs of Tapinarof, e.g., Tapinarof crystalline Form B, Form C, and Form D, pharmaceutical compositions comprising the same, processes for preparation thereof, and uses thereof for treatment of skin disorders.
Moshe Arkin, Natalie Utsis, Ariel Mitelman, Bar Havazelt, Shai Dan
Filed: 8 May 23
Utility
Treatment of Skin Disorders with Topical Tapinarof Compositions
2 Nov 23
Moshe ARKIN, Danil Finkel-Moiseev, Hila Hakak Djerbi, Karine Neimann
Filed: 11 Jul 23
Utility
Stabilized Microcapsules, Method of Their Preparation and Uses Thereof
26 Oct 23
The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.
Ofer TOLEDANO, Karine NEIMANN, Danil FINKEL-MOISEEV, Maya ERLICH, Dorit MARCO
Filed: 30 Mar 23
Utility
Topical Roflumilast Compositions and Uses Thereof
5 Oct 23
The present disclosure, in some embodiments, relates to a low permeable topical composition comprising roflumilast, N-oxide of roflumilast or salts thereof, and to a method of treatment of a skin disorder by topical administration of said composition.
Moshe ARKIN, Ofer TOLEDANO, Karine NEIMANN, Hila HAKAK DJERBI
Filed: 24 Aug 21
Utility
Method for Therapeutic Treatment of Rosacea
10 Aug 23
A regimen and a pharmaceutical composition for the treatment of a skin condition and/or skin affliction are described.
Ofer TOLEDANO, Ori NOV
Filed: 20 Mar 23
Utility
Treatment of skin disorders with compositions comprising an EGFR inhibitor
25 Apr 23
This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib.
Moshe Arkin, Marcel Zighelboim, Ori Nov, Ofer Toledano, Karine Neimann
Filed: 8 Jan 20
Utility
Method for therapeutic treatment of rosacea
18 Apr 23
A regimen and a pharmaceutical composition for the treatment of rosacea are described.
Ofer Toledano, Ori Nov
Filed: 19 Feb 20
Utility
Method for Treatment of Rosacea
6 Apr 23
A regimen is described for the therapeutic treatment of rosacea.
Moshe ARKIN, Karine NEIMANN, Ofer TOLEDANO
Filed: 7 Dec 22
Utility
Method for Treatment of Rosacea In Patients Aged 35-64 Years
9 Mar 23
A regimen for the therapeutic treatment of rosacea in a subject aged 35-64 years, the regimen comprising topically applying a pharmaceutical composition to the skin of the subject in need of said treatment, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, to achieve, in a group of such subjects, a success rate of at least about 12%, at least about 27%, at least about 38%, or at least about 42%, respectively, and wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
Filed: 22 Aug 22
Utility
Treatment of Skin Disorders with Topical Compositions Comprising Tapinarof and a PDE4 Inhibitor
5 Jan 23
Provided herein is a topical combination composition comprising tapinarof, a PDE4 inhibitor and optionally at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof.
Moshe ARKIN, Marcel ZIGHELBOIM, Karine NEIMANN
Filed: 24 Nov 20
Utility
Method for treatment of rosacea
3 Jan 23
A regimen is described for the therapeutic treatment of rosacea.
Moshe Arkin, Karine Neimann, Ofer Toledano
Filed: 3 Dec 21
Utility
Treatment of Cutaneous Adverse Effects Caused by Oncological Therapy with Topical Tapinarof Compositions
8 Dec 22
Provided herein is a topical composition comprising tapinarof and methods of treatment of cutaneous adverse effects caused by oncological therapy with the tapinarof composition.
Moshe ARKIN, Marcel ZIGHELBOIM
Filed: 24 Sep 20
Utility
Method for Long-term Treatment of Rosacea
17 Nov 22
A regimen for the long-term therapeutic treatment of rosacea.
Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
Filed: 20 Jul 22
Utility
Treatment of Skin Disorders with Topical Combination Compositions Comprising Tapinarof and an Additional Ahr Activator
20 Oct 22
Provided herein is a topical combination composition comprising tapinarof, an additional AhR activator and optionally further comprising at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof.
Moshe ARKIN, Marcel ZIGHELBOIM
Filed: 24 Sep 20
Utility
Topical Jak Inhibitor Combination Compositions for Treatment of Inflammatory Skin Conditions
15 Sep 22
Provided herein is a topical combination composition and a method of treatment of an inflammatory skin condition by administration of said composition comprising at least one Janus kinase inhibitor (JAK inhibitor) and at least one additional active agent elected from benzoyl peroxide (BPO), at least one retinoid, tapinarof, at least one antibiotic, at least one antiandrogen, at least one acaricide and combinations thereof and a carrier suitable for topical administration.
Moshe ARKIN, Marcel ZIGHELBOIM, Ori NOV, Ofer TOLEDANO
Filed: 23 Jul 20